Recombinant SARS-CoV-2 S1 Subunit Protein (RBD), mutant N501Y

Functional Assay, Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.

C-terminal his-tag

-20°C

Recombinant SARS-CoV-2 S1 Subunit Protein (RBD) mutant N501Y with C-terminal His-tag, derived from the transfected human HEK293 cells.

S

Supplied as a 0.2 µm filtered solution in PBS (pH 7.4)

Spike protein, S Protein, S1 Subunit, Host Cell Receptor Binding Domain (RBD)

Lot specific (see the label on the vial), determined by BCA protein assay

Figure 1.Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size (ˆ¼25 kDa), thus indicating that the untreated recombinant protein (Lane 2, ˆ¼30 kDa) was glycosylated.Lane 1: Protein standard ladder (kDa)Lane 2: Untreated proteinLane 3: Treated protein with deglycosylation enzymes under native conditions.Lane 4: Treated protein with deglycosylation enzymes under denature conditions.Lane 5: Deglycosylation enzymes only without target proteins.

Product binding ability was measured by ELISA. The immobilized recombinant human ACE2 protein (Catalog #230-30165, coated at 0.5 ug/ml, 100 ul/well) was incubated with the serial diluted SARS CoV-2 S1 RBD N501Y mutant protein (Catalog #230-30184). The bound mutant protein was detected by mouse anti-S1 RBD monoclonal antibody using ELISA. The calculated EC50 is 63.06 ng/ml.